[go: up one dir, main page]

NO20071315L - Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen. - Google Patents

Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.

Info

Publication number
NO20071315L
NO20071315L NO20071315A NO20071315A NO20071315L NO 20071315 L NO20071315 L NO 20071315L NO 20071315 A NO20071315 A NO 20071315A NO 20071315 A NO20071315 A NO 20071315A NO 20071315 L NO20071315 L NO 20071315L
Authority
NO
Norway
Prior art keywords
active principle
pharmaceutical preparation
tablet containing
abdominal distention
abdominal
Prior art date
Application number
NO20071315A
Other languages
English (en)
Inventor
Gerard Alaux
Estelle Chouin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071315(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20071315L publication Critical patent/NO20071315L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet et farmasøytisk preparat i form av en matrikstablett omfattende et aktivt prinsipp, for opphold i magen, kjermetegnet ved at når det bringes i kontakt med et miljø som representerer et magefiuid øker det etter 15 minutter i volum med en svellerate på minst 200 %.
NO20071315A 2004-08-19 2007-03-09 Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen. NO20071315L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
PCT/FR2005/002092 WO2006021692A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif

Publications (1)

Publication Number Publication Date
NO20071315L true NO20071315L (no) 2007-03-09

Family

ID=34950702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071315A NO20071315L (no) 2004-08-19 2007-03-09 Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.

Country Status (22)

Country Link
US (1) US20070190140A1 (no)
EP (1) EP1781295A1 (no)
JP (1) JP5048492B2 (no)
KR (1) KR20070046124A (no)
CN (1) CN101022808B (no)
AR (1) AR050696A1 (no)
AU (1) AU2005276307B2 (no)
BR (1) BRPI0514532A (no)
CA (1) CA2577361C (no)
EA (1) EA012981B1 (no)
FR (1) FR2874325B1 (no)
IL (1) IL181150A0 (no)
MA (1) MA28862B1 (no)
MX (1) MX2007001957A (no)
MY (1) MY145832A (no)
NO (1) NO20071315L (no)
NZ (1) NZ553673A (no)
PE (1) PE20060639A1 (no)
TW (1) TWI357329B (no)
UY (1) UY29073A1 (no)
WO (1) WO2006021692A1 (no)
ZA (1) ZA200701443B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2124884T3 (pl) 2006-12-22 2020-01-31 Ironwood Pharmaceuticals, Inc. Metody i kompozycje do leczenia zaburzeń przełyku
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
BRPI0915284B1 (pt) 2008-06-30 2020-01-14 Tocagen Inc composição farmacêutica oral, e, uso de uma composição farmacêutica
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10245034B2 (en) * 2015-08-31 2019-04-02 Ethicon Llc Inducing tissue adhesions using surgical adjuncts and medicants
CN112426519A (zh) * 2020-11-29 2021-03-02 长沙晶易医药科技有限公司 一种含乙醇脱氢酶和乙醛脱氢酶的胃滞留缓释制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
SK284388B6 (sk) * 1996-08-29 2005-02-04 Sanofi-Synthelabo Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
WO2002000213A1 (en) * 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881424B1 (en) * 2000-09-05 2005-04-19 Mionix Corporation Highly acidic metalated organic acid
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
AU2002355686B2 (en) * 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors

Also Published As

Publication number Publication date
HK1112575A1 (en) 2008-09-12
IL181150A0 (en) 2007-07-04
MX2007001957A (es) 2007-04-25
TW200618802A (en) 2006-06-16
WO2006021692A8 (fr) 2007-04-12
ZA200701443B (en) 2008-05-25
AR050696A1 (es) 2006-11-15
EP1781295A1 (fr) 2007-05-09
MY145832A (en) 2012-04-30
UY29073A1 (es) 2006-03-31
BRPI0514532A (pt) 2008-06-17
NZ553673A (en) 2010-10-29
JP5048492B2 (ja) 2012-10-17
EA200700217A1 (ru) 2007-08-31
TWI357329B (en) 2012-02-01
MA28862B1 (fr) 2007-09-03
WO2006021692A1 (fr) 2006-03-02
CA2577361A1 (fr) 2006-03-02
KR20070046124A (ko) 2007-05-02
CA2577361C (fr) 2013-10-01
JP2008509973A (ja) 2008-04-03
CN101022808A (zh) 2007-08-22
PE20060639A1 (es) 2006-07-20
CN101022808B (zh) 2013-05-29
AU2005276307B2 (en) 2011-02-24
FR2874325A1 (fr) 2006-02-24
US20070190140A1 (en) 2007-08-16
FR2874325B1 (fr) 2006-10-20
EA012981B1 (ru) 2010-02-26
AU2005276307A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
NO20071315L (no) Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.
AR048331A1 (es) Sistema de administracion de farmacos con retencion gastrica
WO2006128471A3 (en) A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
BR0211317A (pt) Sistema para a liberação controlada de uma droga por meio de retenção gástrica
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2008048777A3 (en) Luer activated device
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
NO20064094L (no) Partikler
IL163659A0 (en) Acc inhibitors
WO2008138936A3 (de) Zerstäuber und filter
WO2008013710A3 (en) Chewable tablet containing phenylephrine
WO2007024949A3 (en) Alpha2c adrenoreceptor agonists
WO2008017018A3 (en) Kinetic gas hydrate inhibitors in completion fluids
WO2008027963A3 (en) Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP1561472A4 (en) SOLID PREPARATION
WO2007089934A3 (en) Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
WO2008052468A8 (en) New lactobacillus rhamnosus strain, its pharmaceutical composition and the uses thereof, and the method for preparation
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2006021160A8 (fr) Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application